Ankündigung • Mar 10
Aptorum Group Limited and DiamiR Biosciences Corp Announce Publication of MicroRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens Aptorum Group Limited and DiamiR Biosciences Corp. announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics, a peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, conducted in collaboration with clinical researchers at the Perelman School of Medicine at the University of Pennsylvania, demonstrates the feasibility of detecting glioblastoma (GBM) — the most aggressive and lethal form of brain cancer — through a minimally invasive blood plasma test. The research identifies specific microRNA signatures in blood plasma that show significant promise as non-invasive biomarkers for glioblastoma diagnosis and monitoring. GBM is among the deadliest of all human cancers, with a median survival of fewer than 15 months following diagnosis. Current diagnostic approaches rely on invasive surgical biopsies or costly imaging procedures. DiamiR’s microRNA platform represents a potential paradigm shift, one that the company believe will enable earlier detection and improve patient monitoring through a simple blood draw. Ankündigung • Feb 09
Aptorum Group Limited, Annual General Meeting, Mar 10, 2026 Aptorum Group Limited, Annual General Meeting, Mar 10, 2026, at 09:00 China Standard Time. Location: 17/f., guangdong investment tower, 148 connaught road central, Hong Kong New Risk • Dec 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$8.96m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$8.96m market cap). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Ankündigung • Oct 11
Aptorum Group Limited has filed a Follow-on Equity Offering in the amount of $2 million. Aptorum Group Limited has filed a Follow-on Equity Offering in the amount of $2 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,000,000
Price\Range: $2
Transaction Features: Registered Direct Offering Ankündigung • Oct 10
Aptorum Group Limited Announces Board and Executive Appointments Aptorum Group Limited announced the addition of Dr. Laura A. Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp. Dr. Philips is the co-founder, President, and Chief Executive Officer of Spheryx Inc., a technology company developing holographic microscopic techniques for a broad range of applications in areas including the pharmaceutical industry, semiconductor manufacturing, cosmetics, consumer products, quality assurance, and process control. In addition to co-founding Spheryx in 2014, Dr. Philips has served on the Boards of Directors of multiple private and public life sciences companies, including WellGen Inc., Delcath Systems, and China Yongxin Pharmaceuticals. From 2003-2006, Dr. Philips was COO and Chief Financial Officer at NexGenix Pharmaceuticals. She held a variety of executive positions at Corning Incorporated from 1997-2002. Dr. Philips served in the Clinton Administration both as a Fellow in the White House Office of Science and Technology Policy and as a Presidential Appointee in the position of Senior Policy Advisor to Secretary Ronald Brown in the Department of Commerce. Dr. Philips holds a Ph.D. in Chemistry from the University of California, Berkeley, and an MBA from Cornell University, and was on the Faculty of Cornell University in the Department of Chemistry from 1987-1993. As was previously announced on July 16, 2025, Aptorum Group and DiamiR entered into a definitive agreement for an all-stock merger transaction. As a result of this transaction and subject to stockholder approval of both companies and customary closing conditions, DiamiR will become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger. The transaction is expected to close in the fourth quarter of 2025. Once the merger is closed, Dr. Kira Sheinerman, DiamiR’s co-founder and director, will be joining the combined company board as a director, and Dr. Alidad Mireskandari, DiamiR’s Chief Executive Officer, will be taking an observer seat on the board and joining the combined company as its President and Chief Operating Officer. Dr. Mireskandari has extensive life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences from 2013 to 2022, and prior to that as President & Chief Executive Officer of JS Genetics from 2009 to 2013. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors. Dr. Mireskandari holds a Ph.D. in Genetics from George Washington University and an MBA from the University of Michigan Ross School of Business. Dr. Sheinerman is DiamiR’s co-founder and Executive Director. Since November 2015, she has served as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co., where she works on financial and strategic transactions for growth life sciences companies. Previously, she was a Managing Director of Healthcare Investment Banking at Rodman & Renshaw from 2005 to 2012. From 2015 through 2018 she served as the founding co-chair of Alzheimer’s Association Business Consortium. Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer’s Disease. Dr. Sheinerman also holds an Honors MBA from the Zicklin School of Business, Baruch College/CUNY. Ankündigung • Aug 21
DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test DiamiR Biosciences Corp. and Aptorum Group Limited announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). This milestone allows DiamiR to offer its validated APOE Genotyping molecular testing in a variety of biological samples, such as blood, buccal swab, saliva, and tissue, through its Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited clinical laboratory by licensed healthcare providers in New York State and nationwide. New York State DOH CLEP is known for having stringent validation standards for laboratory-developed tests (LDTs). Clinical laboratories testing biospecimens from New York residents must obtain a clinical laboratory permit from NYSDOH to help ensure the accuracy and reliability of clinical tests. Ankündigung • Jul 16
DiamiR Biosciences Corp. entered into a definitive agreement to acquire Aptorum Group Limited (NasdaqCM:APM) in a reverse merger transaction. DiamiR Biosciences Corp. entered into a definitive agreement to acquire Aptorum Group Limited (NasdaqCM:APM) in a reverse merger transaction on July 16, 2025. Under the terms of the merger agreement and subject to stockholder approval, Aptorum Group will re-domicile to the state of Delaware prior to the closing of the merger, and following the Domestication, acquire all of the outstanding capital stock of DiamiR Biosciences in exchange for a number of shares of its common stock which will represent approximately 70% of the outstanding common stock of Aptorum Group, with the current equity holders of Aptorum Group retaining 30% of the common stock immediately following the consummation of the merger. DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger. Following the merger, the combined company will be headquartered in Princeton, New Jersey, and the executive officers are expected to be Ian Huen as Chief Executive Officer, Dr. Alidad Mireskandari as President and Chief Operating officer, and Gary Anthony as Chief Financial Officer. The merger agreement provides that the board of directors of the combined company will be composed of five members, with three members initially designated by Aptorum Group and two members and one board observer initially designated by DiamiR. The merger agreement has been approved by the boards of directors of both companies, and is subject to stockholder approval of both companies, certain third party consents, a registration statement on Form S-4 and other customary closing conditions. The proposed merger is expected to close in the fourth quarter 2025. Hunter Taubman Fischer & Li LLC is acting as legal counsel to Aptorum Group while Ellenoff Grossman & Schole LLP is acting as legal counsel to DiamiR Biosciences. H.C. Wainwright & Co. is acting as financial advisor to DiamiR. Ankündigung • Apr 18
Aptorum Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Aptorum Group Limited announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until 14 October 2025, to regain compliance with the continued listing requirements. During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame. Ankündigung • Jan 04
Aptorum Group Limited has filed a Follow-on Equity Offering in the amount of $3.07 million. Aptorum Group Limited has filed a Follow-on Equity Offering in the amount of $3.07 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,535,000
Price\Range: $2
Discount Per Security: $0.14
Transaction Features: Registered Direct Offering Ankündigung • Nov 11
Aptorum Group Limited, Annual General Meeting, Dec 10, 2024 Aptorum Group Limited, Annual General Meeting, Dec 10, 2024. Location: 17/f., guangdong investment tower, 148 connaught road central, Hong Kong Ankündigung • Mar 07
YOOV Group Holding Limited entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited (NasdaqGM:APM) from Jurchen Investment Corporation and others for $250 million in a reverse merger transaction. YOOV Group Holding Limited entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited (NasdaqGM:APM) from Jurchen Investment Corporation and others for $250 million in a reverse merger transaction on March 1, 2024. Aptorum agreed to issue Class A ordinary shares, and Class B ordinary shares, to YOOV's shareholders. The total number of ordinary shares of Aptorum to be issued in the merger equals the number of aggregate fully diluted shares of YOOV multiply by the "Conversion Ratio." The Conversion Ratio is calculated by dividing (i) Aptorum's outstanding Class A ordinary shares and Class B ordinary shares multiplied by nine (ii) by the aggregate fully diluted shares of YOOV. Upon completion of the Merger, the existing Aptorum shareholders and existing YOOV shareholders expect to own approximately 10% and 90%, respectively, of the outstanding shares of the combined company. Upon termination, YOOV shall reimburse Aptorum 90% of all expenses actually incurred by YOOV and Merger Sub in connection with the Proposed Transactions, not exceeding $1,000,000. Such reimbursement shall occur promptly within 30 days upon demand by Aptorum, except if termination arises from Force Majeure. In related transaction, on March 1, 2024, Aptorum, its major shareholder, Jurchen Investment, Aptorum, and Aptorum Therapeutics Limited (ATL), a wholly-owned subsidiary of Aptorum have entered into a split-off agreement, Aptorum will assign and transfer the assets and liabilities of its legacy business to ATL, and Jurchen will acquire 100% issued and outstanding shares of ATL from Aptorum and surrender certain ordinary shares of Aptorum held by Jurchen to Aptorum.
The Merger Agreement was unanimously approved by Aptorum’s and YOOV’s boards of directors, respectively. The closing of the Merger is subject to satisfaction or waiver of certain conditions including, but not limited to obtaining the approval by the shareholders of Aptorum and YOOV of the matters required under the Merger Agreement; approval of the Initial Listing Application by Nasdaq; delivery of legal opinions from British Virgin Islands counsel and Cayman Islands counsel and Hong Kong counsel of YOOV to Aptorum; delivery of a fairness opinion by Colliers International (Hong Kong) Limited to the Board of Aptorum to the effect that (subject to various qualifications and assumptions) that merger consideration the total Class A ordinary shares and Class B ordinary shares to be issued to YOOV's shareholders) is fair, from a financial point of view (based on the conclusion that the equity value of YOOV is no less than $250 million), to the shareholders of Aptorum; availability of audited financial statements for YOOV and its Subsidiaries; and fully executed lock-up agreement and support agreement by Aptorum and YOOV.
Jay Knight and Naomi Kwang of Barnes & Thornburg LLP, Harney Westwood & Riegels and Stephenson Harwood acted as legal advisors to YOOV, Hunter Taubman Fischer & Li LLC and Colliers International (Hong Kong) Limited acted as advisors to Aptorum. Ankündigung • Nov 17
Aptorum Group Limited, Annual General Meeting, Dec 20, 2023 Aptorum Group Limited, Annual General Meeting, Dec 20, 2023, at 08:00 US Eastern Standard Time. Location: London office located at 17 Hanover Square, Mayfair London, England W1S 1BN Mayfair London United Kingdom Ankündigung • Sep 13
Aptorum Group Limited announced that it has received $3 million in funding from Jurchen Investment Corporation Aptorum Group Limited announced that it has entered into a securities purchase agreement to issue convertible notes for the gross proceeds of $3 million on September 11, 2023. The notes have a coupon rate of 6% and the notes will be convertible into class A ordinary shares at a conversion price of $2.42 per share and have a maturity date that is 24 months from the issuance date. Ankündigung • Aug 11
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets Aptorum Group Limited announced that it has received an approval letter from the Nasdaq Stock Market LLC Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market. On this basis, the previous two listing deficiencies regarding minimum stockholder’s equity and minimum market value of publicly held shares will be closed. The trading of its Class A ordinary shares will continue on Nasdaq and will not be affected. Ankündigung • Jun 23
Aptorum Group Limited Provides Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma Aptorum Group Limited announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, anally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA. The Phase 1b/2a study of SACT-1 submitted is for the combination with chemotherapy for first relapse or refractory high risk neuroblastoma. This Phase 1b/2a trial represents another key milestone for the company and one of the targeted strategic goals for the year of 2023. Neuroblastoma is a solid tumor arising in the nervous system outside of the brain predominantly in pediatric patients. The clinical behavior of neuroblastoma is highly variable with majority cases being highly aggressive. SACT-1 has the potential to effectively target this disease and address the unmet demands of such. The targeted objectives of the Phase 1b part of the study based on neuroblastoma patients to be enrolled is to determine the recommended phase 2 dose (RP2D) based on safety, pharmacokinetics and efficacy and the Phase 2a part of the study based on Neuroblastoma patients to be enrolled will be used to assess the preliminary efficacy of SACT-1. SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated in preclinical studies to enhance tumor cell death and suppress MYCN expression (a common clinical diagnosis in high-risk or relapsed neuroblastoma patients where an amplification of MYCN is usually observed). SACT-1 is designed to be used especially in combination with standard-of-care chemotherapy. Ankündigung • Jun 12
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris Aptorum Group Limited (the “Company”) announced that following a comprehensive review of the trading volume, costs and administrative requirements related to its listing on Euronext Paris, it has decided to request the voluntary delisting of its shares (the “Aptorum Shares”) (ISIN KYG6096M1226) from Euronext Paris. The Board of Euronext has approved this request. Following the delisting from Euronext Paris, the Aptorum Shares will remain listed on the NASDAQ (the “NASDAQ”), the Company’s primary listing exchange. Delisting the Aptorum Shares from Euronext Paris has no impact on the NASDAQ listing of Aptorum Shares. Aptorum Shares will be delisted from Euronext Paris on July 5, 2023. Aptorum Shares will continue to be listed on the NASDAQ. Reported Earnings • May 01
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: US$2.75 loss per share (improved from US$7.15 loss in FY 2021). Net loss: US$9.80m (loss narrowed 61% from FY 2021). Revenue missed analyst estimates by 63%. Earnings per share (EPS) exceeded analyst estimates by 45%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 16
Price target decreased to US$11.50 Down from US$14.67, the current price target is an average from 2 analysts. New target price is 1,616% above last closing price of US$0.67. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$0.59 next year compared to a net loss per share of US$0.71 last year. Price Target Changed • Oct 11
Price target decreased to US$11.50 Down from US$14.67, the current price target is an average from 2 analysts. New target price is 1,279% above last closing price of US$0.83. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$0.62 next year compared to a net loss per share of US$0.71 last year. Reported Earnings • Oct 01
First half 2022 earnings released: US$0.053 loss per share (vs US$0.47 loss in 1H 2021) First half 2022 results: US$0.053 loss per share (improved from US$0.47 loss in 1H 2021). Net loss: US$1.89m (loss narrowed 88% from 1H 2021). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jun 28
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$1.00 to -US$0.83 per share. Revenue forecast unchanged from US$1.50m at last update. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$15.00 unchanged from last update. Share price rose 4.4% to US$1.31 over the past week. Reported Earnings • May 01
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Net loss: US$25.0m (down 497% from profit in FY 2020). Revenue exceeded analyst estimates by 28%. Over the next year, revenue is expected to shrink by 2.7% compared to a 44% growth forecast for the pharmaceuticals industry in the US. Reported Earnings • Sep 18
First half 2021 earnings released: US$0.47 loss per share (vs US$0.21 loss in 1H 2020) First half 2021 results: Net loss: US$16.1m (loss widened 159% from 1H 2020). Executive Departure • Sep 02
Chief Operating Officer Siu-yan Ng has left the company On the 27th of August, Siu-yan Ng's tenure as Chief Operating Officer ended after 2.4 years in the role. We don't have any record of a personal shareholding under Siu-yan's name. Siu-yan is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.71 years. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment improved over the past week After last week's 18% share price gain to US$3.43, the stock trades at a trailing P/E ratio of 16.9x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 19% over the past year. Valuation Update With 7 Day Price Move • May 27
Investor sentiment improved over the past week After last week's 16% share price gain to US$2.76, the stock trades at a trailing P/E ratio of 13.6x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 10% over the past year. Reported Earnings • Apr 24
Full year 2020 earnings released: EPS US$0.20 (vs US$0.64 loss in FY 2019) Full year 2020 results: Net income: US$6.31m (up US$25.0m from FY 2019). Products in clinical trials Phase I: 1 Is New 90 Day High Low • Feb 18
New 90-day high: US$4.17 The company is up 73% from its price of US$2.41 on 19 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$31.61 per share. Is New 90 Day High Low • Jan 16
New 90-day high: US$3.31 The company is up 20% from its price of US$2.76 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$31.35 per share. Is New 90 Day High Low • Sep 29
New 90-day low: US$1.22 The company is down 68% from its price of US$3.79 on 30 June 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2,350 per share.